Abatacept as a therapeutic option in the treatment of encapsulated peritoneal sclerosis: an experimental rat model


Bircan L., KARAKÖSE S., Unverdi H., Bal A. Z., Unverdi S., DURANAY M.

International Urology and Nephrology, cilt.49, sa.5, ss.909-916, 2017 (SCI-Expanded, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 49 Sayı: 5
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1007/s11255-017-1535-9
  • Dergi Adı: International Urology and Nephrology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.909-916
  • Anahtar Kelimeler: Abatacept, Encapsulated peritoneal sclerosis, Matrix metalloproteinase-2, Transforming growth factor-beta-1
  • Sağlık Bilimleri Üniversitesi Adresli: Evet

Özet

Purpose: Encapsulated peritoneal sclerosis (EPS) is a rare complication of long-term peritoneal dialysis (PD) and is usually associated with mortality. Inflammation is a leading factor for developing EPS. This study aimed to investigate the effect of abatacept on peritoneal fibrosis and inflammation using the EPS rat model. Methods: Twenty-four Wistar albino rats were randomly divided into four equal groups. Group I (control group) was administered isotonic saline (IS) via the intraperitoneal (ip) route during weeks 0–3. Chlorhexidine gluconate (CG) ip was administered to group II (CG group) during weeks 0–3. Group III (CG + IS group) received CG for the first 21 days and IS solution for the following 3 weeks. Group IV (abatacept group) received CG during weeks 0–3, and subsequently, 50 mcg/day abatacept during weeks 4–6. Peritoneal thickness, fibrosis, and inflammation were examined using light microscopy. Expressions of matrix metalloproteinase-2 (MMP-2) and transforming growth factor-beta 1 (TGF-β1) were detected by immunohistochemical staining. Results: Lesser peritoneal thickness and lower inflammation score were observed in the abatacept group than in the CG and CG + IS groups (p < 0.05). Furthermore, the abatacept group had a lower fibrosis score than the CG + IS group (p < 0.05). MMP-2 and TGF-β1 scores were lower in the abatacept group than in the CG + IS group (p < 0.05). Conclusions: The results revealed that abatacept had a histopathological beneficial effect on peritoneal fibrosis, inflammation, MMP-2, and TGF-β1 scores, which were induced by CG. Abatacept could be a new therapeutic option for treating EPS.